UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Snowmelt

Palliative & supportive care, 2024-06, Vol.22 (3), p.628-628

Gandhi, Malini M

2024

Volltextzugriff (PDF)

Trypan Blue

JAMA : the journal of the American Medical Association, 2019-06, Vol.321 (21), p.2137

Gandhi, Malini M.

2019

Volltextzugriff (PDF)

Drift

JAMA : the journal of the American Medical Association, 2019-05, Vol.321 (20), p.2036

Gandhi, Malini M.

2019

Volltextzugriff (PDF)

Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation

AIDS (London), 2024-03, Vol.38 (3), p.317-327

2024

Volltextzugriff (PDF)

Evaluation of GeneXpert and advanced biological laboratories UltraGene HCV diagnostic detection and performance against Roche real time PCR in Myanmar

Journal of clinical virology, 2024-04, Vol.171, p.105653, Article 105653

2024

Volltextzugriff (PDF)

Barriers to hepatitis C direct‐acting antiviral therapy among HIV/hepatitis C virus‐coinfected persons

Journal of gastroenterology and hepatology, 2021-04, Vol.36 (4), p.1095-1102

2021

Volltextzugriff (PDF)

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Cancer discovery, 2024-08, Vol.14 (8), p.1440-1456

2024

Volltextzugriff (PDF)

Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus‐co‐infected patients in Myanmar

Journal of viral hepatitis, 2021-01, Vol.28 (1), p.147-158

2021

Volltextzugriff (PDF)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (11), p.e007618

2023

Volltextzugriff (PDF)

Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma

JCO precision oncology, 2024-10, Vol.8 (8), p.e2400394

2024

Volltextzugriff (PDF)

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO precision oncology, 2023-09, Vol.7 (7), p.e2300295

2023

Volltextzugriff (PDF)

192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A219-A220

2023

Volltextzugriff (PDF)

218 Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient pan-cancer cohort

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A249-A249

2023

Volltextzugriff (PDF)

Estimating kidney function in patients with cancer: A narrative review

Acta Physiologica, 2023-06, Vol.238 (2), p.e13977-n/a

2023

Volltextzugriff (PDF)

Clinical, pathologic, and genomic hallmarks of KRAS -amplified non-small cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9118-9118

2023

Volltextzugriff (PDF)

Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9127-9127

2023

Volltextzugriff (PDF)

TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8608-8608

2024

Volltextzugriff (PDF)

Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8633-8633

2024

Volltextzugriff (PDF)

Barriers to Hepatitis C Direct-acting Antiviral Therapy among HIV/HCV-Coinfected Persons

Journal of gastroenterology and hepatology, 2020-09, Vol.36 (4), p.1095-1102

2020

Volltextzugriff (PDF)

Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9123-9123

2023

Volltextzugriff (PDF)

Abstract 5064: Wild type KRAS amplification as de novo oncogenic driver in non-small cell lung cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5064-5064

2024

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Humans
(19)
Life Sciences & Biomedicine
(19)
Oncology
(9)
Lung Neoplasms - Genetics
(7)
Male
(7)
Lung Neoplasms - Drug Therapy
(6)
Biomarkers
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Hiv
(5)
Cancer
(4)
Carcinoma, Non-Small-Cell Lung - Pathology
(4)
Chemistry
(4)
Female
(4)
Hepatitis C
(4)
Immunotherapy
(4)
Lung Neoplasms - Pathology
(4)
Mutation
(4)
Patients
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Snowmelt

Trypan Blue

Drift

Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC

Evaluation of GeneXpert and advanced biological laboratories UltraGene HCV diagnostic detection and performance against Roche real time PCR in Myanmar

Barriers to hepatitis C direct‐acting antiviral therapy among HIV/hepatitis C virus‐coinfected persons

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus‐co‐infected patients in Myanmar

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co‐infected patients in Ukraine

192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma

218 Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient pan-cancer cohort

Estimating kidney function in patients with cancer: A narrative review

Clinical, pathologic, and genomic hallmarks of KRAS -amplified non-small cell lung cancer

Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer

TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma

Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer

Barriers to Hepatitis C Direct-acting Antiviral Therapy among HIV/HCV-Coinfected Persons

Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC)

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer

Abstract 5064: Wild type KRAS amplification as de novo oncogenic driver in non-small cell lung cancer

Suchergebnisse filtern